Clinical Trials Using Ponatinib Hydrochloride

Clinical trials are research studies that involve people. The clinical trials on this list are studying Ponatinib Hydrochloride. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-5 of 5
  • Testing the Use of Steroids and Tyrosine Kinase Inhibitors with Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

    This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager (‘BiTE’) that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.
    Location: 105 locations

  • Ponatinib for the Treatment of Advanced and Metastatic Medullary Thyroid Cancer

    This phase II trial studies how well ponatinib works in treating patients with medullary thyroid cancer that has spread to other places in the body (advanced and metastatic). Ponatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • Venetoclax, Ponatinib, and Dexamethasone in Patients with Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

    This phase I / II trial studies the best dose of venetoclax when given together with ponatinib and dexamethasone and to see how well they work in treating patients with Philadelphia chromosome or BCR-ABL positive acute lymphoblastic leukemia or chronic myelogenous leukemia that has come back (relapsed) or does not respond to treatment (refractory). Drugs used in chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ponatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Anti-inflammatory drugs, such as dexamethasone lower the body’s immune response and are used with other drugs in the treatment of some types of cancer. Giving venetoclax, ponatinib, and dexamethasone may work better in treating patients with acute lymphoblastic leukemia or chronic myelogenous leukemia.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Ponatinib in Treating Patients with Refractory Metastatic Cancers and Genetic Alterations

    This phase II trial studies how well ponatinib works in treating patients with cancer that has spread to other parts of the body (metastatic), did not respond to previous treatment (refractory), and has one of several alterations, or mutations, in its deoxyribonucleic acid (DNA) sequence. Ponatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether a patient's genetic alterations may affect how well ponatinib hydrochloride works.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Ponatinib Hydrochloride as Second Line Therapy in Treating Patients with Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

    This phase II trial studies how well ponatinib hydrochloride works as second line therapy in treating patients with chronic myeloid leukemia in chronic phase that has not responded to initial treatment (first line) with imatinib mesylate, dasatinib, or nilotinib or cannot tolerate imatinib mesylate, dasatinib, or nilotinib. Ponatinib hydrochloride may stop or control the growth of cancer cells by blocking a protein needed for cell growth.
    Location: M D Anderson Cancer Center, Houston, Texas